Table 2.

Factors associated with transitions in smoking and vaping status among baseline exclusive daily smokers

	No transition	Transition to vaping			Transition to quitting
	n=3857	n=548			n=581
	%, mean	%, mean	ARR (95% CI)†	p-value	%, mean	ARR (95% CI)†	p-value
NVP discussion
No discussion	77.7%	12.0%	1 (referent)		13.5%	1 (referent)
NVP recommended	58.9%	37.0%	3.61 (2.06 - 6.34)	<0.001	9.6%	0.93 (0.40 - 2.14)	0.856
NVP not recommended	67.1%	25.5%	2.58 (1.69 - 3.93)	<0.001	16.1%	1.27 (0.78 - 2.07)	0.328
Other cessation advice	82.5%	8.8%	0.79 (0.65 - 0.97)	0.025	10.3%	0.70 (0.58 - 0.85)	<0.001
Country
England	75.9%	16.3%	1 (referent)		11.1%	1 (referent)
Australia	82.8%	8.4%	0.49 (0.37 - 0.65)	<0.001	11.3%	0.92 (0.71 - 1.20)	0.554
Canada	97.4%	12.4%	0.63 (0.50 - 0.80)	<0.001	12.5%	0.98 (0.77 - 1.25)	0.877
US	38.9%	6.6%	0.40 (0.29 - 0.53)	<0.001	12.9%	1.13 (0.87 - 1.46)	0.361
HSI	2.6	2.7	1.11 (1.04 - 1.18)	0.003	2.4	0.94 (0.88 - 1.00)	0.049
Quit attempt
No	82.4%	10.1%	1 (referent)		10.0%	1 (referent)
Yes	74.7%	13.2%	1.25 (1.00 - 1.55)	0.048	15.0%	1.28 (1.04 - 1.58)	0.020
Quit intention
No	82.1%	10.6%	1 (referent)		9.8%	1 (referent)
Yes	73.3%	12.7%	1.13 (0.90 - 1.41)	0.298	16.9%	1.66 (1.34 - 2.05)	<0.001

Transition to vaping: reported use of NVPs at least monthly, either exclusively or concurrently with cigarette smoking. Transition to quitting: reported smoking less than monthly or not at all (stopped smoking), regardless of NVP uptake.

NVP recommended/not recommended: Reported that doctor or health professional talked to them about NVPs and recommended or did not recommend NVPs. Other cessation advice: Reported that doctor or health professional did not talk to them about NVPs but received advice to quit smoking.

^†Models adjusted for all variables listed in the tables, age group, sex, education, income, survey wave, the number of surveys in which respondents participated.

Bolded estimates were significant at p<0.05.